—
Immuno-Oncology Strategic Insight - Multi-Indication And Market Size Analysis Total Immuno-Oncology market will be worth approximately $14 billion in 2019, rising to $34 billion by 2024 in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). The main drivers of this growth will come from immune checkpoint inhibitors, which will have sales of approximately $10 billion in 2019, rising to $24 billion by 2024. The highest-selling IO drugs by 2024 will be Opdivo and Keytruda, both PD-1 inhibitors, with sales of approximately $10 billion and $7 billion, respectively. This is because these two drugs will be first-to-market in many indications, leapfrogging competition such as Roche's atezolizumab and AstraZeneca's durvalumab.Complete report on Immuno-Oncology Strategic Insight - Multi-Indication and Market Size Analysis spread across 423 pages is available at http://www.reportsnreports.com/reports/629512-immuno-oncology-strategic-insight-multi-indication-and-market-size-analysis.html
Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the IO therapeutics market.
List of Tables:
Table 1: Opdivo SWOT Analysis
Table 2: Keytruda SWOT Analysis
Table 3: Atezolizumab SWOT Analysis
Table 4: Durvalumab and Tremelimumab SWOT Analysis
Table 5: Avelumab SWOT Analysis
Table 6: Yervoy SWOT Analysis
Table 7: Immuno-Oncology Cell Therapies SWOT Analysis
Table 8: Cancer Vaccines SWOT Analysis
Table 9: Oncolytic Viruses SWOT Analysis
Table 10: Approved Immuno-Oncology Drugs and Combinations for Advanced Melanoma
Table 11: Approved BRAF/MEK-Targeting Drugs and Combinations for BRAF-Mutated Advanced Melanoma
Table 12: FIGO Guidelines: Staging Classification for Cancer of the Ovary, Fallopian Tube, and Peritoneum
Table 13: Treatment Guidelines for Ovarian Cancer in the 7MM
Table 14: IO + IO Combinations in Phase III Clinical Development
Table 15: PD-L1 Testing Criteria in NSCLC and Clinical Efficacy
Table 16: List of Immuno-oncology Drugs
Request Sample
http://www.reportsnreports.com/contacts/discount.aspx?name=629512
Key Questions Answered
• Development of IO Products has increased significantly in the past three years. Which IO approaches will be the most commercially successful? Which early-stage IO approaches show the most promise?
• Novel combinations will differentiate late-to-market entrants. Which combinations are the most promising for each cancer type? What strategies are IO developers utilizing to differentiate themselves in this crowded market? What collaborations and deals are the most promising?
• NSCLC, melanoma, and myeloma will have the greatest contributions to the IO market in 2019 and 2024. Which diseases are going to be the biggest contributors to the IO market. Which IO product will be the most commercially successful in each disease? Which clinical and commercial strategies are IO developers pursuing in each disease?
Key Findings:
• Opdivo will be the biggest selling IO drug by 2024, with approval forecast in seven indications
• Keytruda will be the second biggest selling IO drug by 2024, with approval forecast in eight indications
• NSCLC, melanoma, and myeloma will have the greatest contributions to the IO market in 2019 and 2024
• Novel combinations will allow late-to-market entrants such as durvalumab to achieve significant sales
Get this Report: http://www.reportsnreports.com/purchase.aspx?name=629512
Scope:
Overview of IO approaches, including checkpoint inhibitors, cell therapies, peptide vaccines, oncolytic viruses, bi-specific antibodies and CAR-T therapies.Revenue by indications for major IO products in 2019 and 2024.Key topics covered include strategic competitor assessment, market characterization,unmet needs, clinical trial mapping and implications for the IO therapeutics market.
Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.Analysis of the current and future market competition in the global IO therapeutics market. Insightful review of the key industry drivers, restraints and challenges. This include analysis of novel combinations and the role of biomarkers such as PD-L1
Reasons to buy:
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list. Develop business strategies by understanding the trends shaping and driving the global multiple myeloma therapeutics market. Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global multiple myeloma therapeutics market in future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors. Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
About Us:
Reportsnreports.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.
Contact Info:
Name: Ritesh Tiwari
Email: Send Email
Organization: ReportsandReports
Address: Pune
Phone: + 1 888 391 5441
Website: http://www.reportsnreports.com/reports/629512-immuno-oncology-strategic-insight-multi-indication-and-market-size-analysis.html
Release ID: 172576
Google
RSS